Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) EPS (Weighted Average and Diluted) (2019 - 2025)

Editas Medicine (EDIT) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.26 as the latest value for Q3 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 65.33% to -$0.26 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$2.35 through Sep 2025, up 7.48% year-over-year, with the annual reading at -$2.88 for FY2024, 42.57% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.26 at Editas Medicine, up from -$0.62 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.21 in Q4 2023, with the low at -$0.92 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.67, with a median of -$0.74 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 76.14% in 2023, then plummeted 161.9% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then crashed by 44.26% to -$0.88 in 2022, then surged by 76.14% to -$0.21 in 2023, then tumbled by 161.9% to -$0.55 in 2024, then soared by 52.73% to -$0.26 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.26, -$0.62, and -$0.92 for Q3 2025, Q2 2025, and Q1 2025 respectively.